

Bone Marrow		Umbilical Cord		Adipose	
Company	Trials	Company	Trials	Company	Trials
Mesoblast	36	Medipost	22	Anterogen	27
Red de Terapia Celular	11	Sclnow Biotechnology	8	Biostar	11
Pharmicell	8	Shenzhen Beike	7	TiGenix	6
Stempeutics Research	8	Translational Biosciences	7	Cellular Biomedicine Group	4
Athersys	7	Shenzhen	5	EHL Bio	2
Banc de Sang i Teixits	7	CardioCell	3	Steminent Biotherapeutics	2
Longeveron	5	Kang Stem Biotech	3	A.A. Partners	1
Brainstorm-Cell Therap.	4	Alliancells Bioscience	2	Ageless Institute	1
Corestem	4	Mesoblast	2	AlloSource	1
Stemedica	4	Banc de Sang i Teixits	1	American CryoStem	1
Apceth	3	Cellonis Biotechnology	1	Bukwang Pharmaceutical	1
Celyad	3	CHABiotech CO	1	Cryopraxis Criobiologia	1
Cytopeutics	3	CytoMed & Beike	1	EMO Biomedicine	1
SanBio	3	Genesis Limited	1	Histocell	1
AlloCure	2	Guangzhou Saliai	1	Hope Biosciences	1
Bone Therapeutics	2	Hebei Newtherapy	1	Kessler Foundation	1
Cellonis Biotechnology	2	Meridigen Biotech Co., Ltd.	1	Nature Cell	1
MD Stem Cells	2	NextCell Pharma Ab	1	Reviva Pharmaceuticals	1
Orbcel	2	Orbcel	1	Rohto Pharmaceutical	1
TCA Cellular Therapy	2	Shandong Qilu Stem Cells	1	Salvat	1
A.A. Partners	1	Shanghai iCELL	1	Stem Cell Medicine	1
Aeon Biotechnology	1	Tianjin Ever Union	1	Stemform	1
Angioblast Systems	1	TOTAL	73	Lipogems	1
Arthrex	1			TOTAL	69
Blackstone Medical	1				
CardioCell	1				
CellMed AG	1				
HomeoTherapy	1				
Orthofix Inc.	1				
Sentien Biotechnologies	1				
Stem Med	1				
Taiwan Bio Therapeutics	1				
Thoratec Corporation	1				
TOTAL	132				

Other		Placenta	
Company	Trials	Company	Trials
Rheacell	5	Pluristem	7
Cellavita	2	Celgene	1
S-Evans Biosciences	2	CHABiotech	1
Genexine	1	TOTAL	9
CAR-T Biotechnology	1		
Cynata Therapeutics	1		
Medistem	1		
TOTAL	13		

Supplemental Fig. 2. Companies involved in clinical trials with MSC. All trials involving participation of companies were selected from our database and the number of trials were counted for each company. The total numbers of trials using different sources of MSC were calculated. This data set is the same shown as numbers of new trials registered in each year in Fig. 3B and represents 32% of all trials.